The U.S. Food and Drug Administration ... animal testing with a new model based on artificial intelligence (AI). This approach, which will be applied to the development of monoclonal antibody ...

Animal testing requirements for monoclonal antibodies and other medications will be “reduced, refined or potentially replaced” in favor of other approaches, including artificial intelligence, ...

The US Food and Drug Administration (FDA) recently announced a strategic roadmap to phase out animal testing requirements for ...

In an unexpected move, the U.S. Food and Drug Administration ... R&D costs and, eventually, the prices for prescription drugs. The agency will encourage researchers to use computer modeling ...

The global biosimulation market, valued at approximately USD 3.1 billion in 2022, is on track to experience significant growth over the next decade. Projected to expand at a compound annual growth ...

Our MSc Model-based Drug Development course provides the knowledge and skills ... methods are so highly valued by industry and regulatory authorities as effective, cost-saving, decision-making tools.

Pharmaceutical industry experts at Gitex Asia 2025 discuss how AI is revolutionising drug discovery, from accelerating ...

The FDA will begin promoting computer-based and lab-grown drug testing models to reduce the cost, time, and ethical burden of drug testing.

The Food and Drug ... the cost of research and development. As part of this move, the FDA is releasing a roadmap for alternative methodologies that will encourage the use of computer modeling ...

The regulatory change is intended to improve drug safety and accelerate the evaluation processing while reducing animal experimentation, lowering research and development costs and lowering drug ...